 |
| 21-Sep-11 | Upgrade |
JMP Securities |
Mkt Perform → Mkt Outperform |
$5 |
|
| 01-Feb-11 | Downgrade |
JMP Securities |
Mkt Outperform → Mkt Perform |
|
|
| 01-Feb-11 | Downgrade |
Canaccord Genuity |
Buy → Hold |
|
|
| 03-Dec-10 | Downgrade |
Rodman & Renshaw |
Mkt Perform → Mkt Underperform |
|
|
| 16-Jul-10 | Reiterated |
JMP Securities |
Mkt Outperform |
$16 → $13 |
|
| 16-Jul-10 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
| 02-Feb-10 | Initiated |
Jefferies & Co |
Buy |
$12 |
|
| 24-Jun-09 | Initiated |
Rodman & Renshaw |
Mkt Outperform |
$14 |
|
| 13-Mar-09 | Reiterated |
Lazard Capital Mkts |
Buy |
$13 → $10 |
|
| 03-Apr-08 | Initiated |
Cowen & Co |
Outperform |
|
|
| 06-Feb-08 | Initiated |
Lazard Capital |
Buy |
|
|
| 04-Feb-08 | Reiterated |
Canaccord Adams |
Buy |
$29 → $32 |
|
| 03-Jan-08 | Initiated |
JP Morgan |
Overweight |
|
|
| 03-Oct-07 | Upgrade |
JMP Securities |
Mkt Outperform → Strong Buy |
$26 |
|
| 07-Jun-07 | Initiated |
JP Morgan |
Overweight |
|
|
| 06-Jun-07 | Initiated |
JMP Securities |
Mkt Outperform |
$26 |
|
|
|
| 20-May-13 02:06PM | The 9 Most Obese Countries in the World at Motley Fool |
| 17-May-13 04:01PM | Orexigen Therapeutics to Present at the UBS Global Healthcare Conference PR Newswire |
| 16-May-13 03:30PM | Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager Finny Kuruvilla Discusses His Portfolio Construction Strategy with The Wall Street Transcript Wall Street Transcript |
| 15-May-13 10:33PM | Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Health Care Conference - Transcript at Seeking Alpha |
| 07:04PM | Weight Loss Isn't Just for Looking Good Anymore at Motley Fool |
| 01:04PM | OREXIGEN THERAPEUTICS, INC. Financials EDGAR Online Financials |
| 08:42AM | Will Obesity Drugs Gain Soon? at Motley Fool |
| 14-May-13 05:49AM | Looking at Arena Following Sell-Off at Motley Fool |
| 05:42AM | Vivus Starting To Gain The Advantage Over Arena at Seeking Alpha |
| 13-May-13 10:35AM | SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc. Business Wire |
| 11-May-13 09:53AM | Why Does Arena's Obesity Drug Have Abuse Potential? at Forbes |
| 10-May-13 04:01PM | Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference PR Newswire |
| 09-May-13 03:20PM | ARNA Sheds Light on Belviq Launch Zacks |
| 08:35AM | VIVUS Reports Wider Loss Zacks |
| 07:17AM | OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 08-May-13 08:34PM | Orexigen Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:00PM | Orexigen Therapeutics, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:49PM | Orexigen Therapeutics, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:01PM | Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013 PR Newswire |
| 01:41PM | Will The Prescription Diet Pill Market Finally Bulk Up? at Forbes |
| 09:06AM | OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 07:37AM | Orexigen Therapeutics, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 07:08AM | Is Orexigen Therapeutics Burning Too Much Cash? at Motley Fool |
| 07:07AM | Q1 2013 Orexigen Therapeutics, Inc. Earnings Release - After Market Close CCBN |
| 07-May-13 12:10PM | Improving Prospects of This Obesity Bet at Motley Fool |
| 11:52AM | SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc. PR Newswire |
| 05-May-13 03:00PM | Are Obesity Drugs a Lost Cause in Europe? at Motley Fool |
| 04-May-13 08:00AM | U.S.-Approved Obesity Drug Derailed in EU at Motley Fool |
| 02-May-13 05:12PM | Arena Withdrawing Obesity Drug Regulatory Application in Europe at Bloomberg |
| 11:17AM | Products with Higher Barriers to Generic Competition Yield Sustained Cash Flows: Expert Analyst David Amsellem Discusses the Brand Specialty Pharma Space with The Wall Street Transcript Wall Street Transcript |
| 08:30AM | Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and Webcast PR Newswire |
| 01-May-13 09:11AM | Vivus And Anti-Obesity Sector Benefit From New Insurance Deal at Seeking Alpha |
| 30-Apr-13 11:15AM | Have Drugmakers Found the Panacea for Obesity? (Part I) at Motley Fool |
| 27-Apr-13 05:36PM | Exciting Catalysts Approaching for This Bet at Motley Fool |
| 25-Apr-13 04:35PM | Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies PR Newswire |
| 12:20PM | Key group's guidelines seen positive for obesity drug makers at theflyonthewall.com |
| 24-Apr-13 03:02PM | These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential at Seeking Alpha |
| 05:47AM | Arena Faces A Convergence Of DEA And European Decisions at Seeking Alpha |
| 23-Apr-13 04:22PM | Anti-Obesity Stocks Are Attractively Priced at Motley Fool |
| 22-Apr-13 08:35AM | Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors PR Newswire |
| 19-Apr-13 10:45AM | Vivus Seeing Traction With Qsymia at Seeking Alpha |
| 07:12AM | The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB Zacks |
| 18-Apr-13 06:30PM | Expanded Access for VIVUS' Qsymia Zacks |
| 17-Apr-13 12:30AM | Vivus Gets Restrictions Loosened at Seeking Alpha +6.16% |
| 16-Apr-13 04:11PM | FDA Makes Obesity Drug Available to More Americans at Motley Fool |
| 11-Apr-13 07:54AM | Vivus May Get Second Wind On Qsymia at Seeking Alpha |
| 10-Apr-13 06:30PM | The Role Medication Plays in Treating Obesity at Motley Fool |
| 06-Apr-13 11:22AM | How Doctors Actually Diagnose Obesity at Motley Fool |
| 04-Apr-13 02:05PM | 10 Flabbergasting Costs of America's Obesity Epidemic at Motley Fool |
| 03-Apr-13 03:28PM | ARNA/Eisai's Belviq Filed in Mexico Zacks |
| 02-Apr-13 06:07PM | Vivus Opts for Royalty Financing Zacks |
| 01:33PM | How Helping Others Lose Weight Could Save You Money at Motley Fool |
| 01-Apr-13 06:01PM | Arena Applies For Launch In Mexico at Seeking Alpha |
| 11:24AM | Should Anti-Obesity Drug Company Stocks Trade In Tandem? at Seeking Alpha |
| 30-Mar-13 02:05PM | Get Paid to Lose Weight at Motley Fool |
| 28-Mar-13 07:50AM | Which Obesity Drug Will Boost Your Portfolio? at Motley Fool +6.28% |
| 27-Mar-13 05:50PM | How's That Long-Term Biotech Investment Looking? at Motley Fool |
| 10:39AM | The Big Weight-Drug Wait at Motley Fool |
| 04:08AM | Vivus Adds Debt - Avoids Dilution at Seeking Alpha |
| 25-Mar-13 01:28PM | Painless Play To Fatten Up Your Portfolio: Buy Arena at Seeking Alpha |
| 23-Mar-13 01:00PM | 5 Hidden Causes of Obesity at Motley Fool |
| 22-Mar-13 08:35PM | 6 Reasons To Buy Arena Pharmaceuticals Right Now at Seeking Alpha |
| 08:05PM | Is Obesity Really a Dangerous Disease? at Motley Fool |
| 20-Mar-13 04:15PM | Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs at Bloomberg |
| 01:04PM | OREXIGEN THERAPEUTICS, INC. Financials EDGAR Online Financials |
| 12:01AM | Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs at Bloomberg |
| 19-Mar-13 12:37PM | Adjust Accordingly: Orexigen's Catalysts May Be Later Than Hoped at Seeking Alpha |
| 17-Mar-13 04:24PM | These Drug Makers Are Letting Growth Opportunities Slide By at Wall St. Cheat Sheet |
| 15-Mar-13 07:24AM | Company News for March 15, 2013 Zacks |
| 14-Mar-13 08:02PM | New Star Analyst Rankings for Orexigen Therapeutics, Inc. StarMine -5.26% |
| 05:21PM | OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online |
| 04:48PM | Loss at OREX Narrower than Expected Zacks |
| 10:13AM | Tick Tock Goes the Obesity Clock at Motley Fool |
| 12:01AM | Arena Pharma Has Plump Profit Potential at Seeking Alpha |
| 13-Mar-13 08:12PM | Orexigen Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 04:54PM | Orexigen Therapeutics, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:06PM | OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 04:01PM | Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012 PR Newswire |
| 07:07AM | Q4 2012 Orexigen Therapeutics, Inc. Earnings Release - After Market Close CCBN |
| 11-Mar-13 09:24AM | Which White-Hot Drug Stocks Have the Strongest Earnings Trends? at Wall St. Cheat Sheet |
| 03:03AM | Is Vivus Under Attack By First Manhattan Co.? at Seeking Alpha |
| 08-Mar-13 06:30PM | The Obesity Drug War Continues at Motley Fool |
| 07-Mar-13 03:55PM | Is Vivus' Run-Up Long Term? at Seeking Alpha |
| 02:45PM | Is the Wait Over? at Motley Fool |
| 08:30AM | Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast PR Newswire |
| 06-Mar-13 06:17PM | Is There a "First-Mover" Advantage in Biotech? at Motley Fool |
| 08:20AM | EnteroMedics and Orexigen Therapeutics Look to Benefit as Medical Costs Associated With Obesity Surpasses Smoking Marketwire |
| 05-Mar-13 04:57AM | A Good Time to Make This Obesity Bet at Motley Fool |
| 04-Mar-13 03:52PM | When Will This Obesity Drug Launch? at Motley Fool +7.28% |
| 03:14PM | When Will This Obesity Drug Launch? at Motley Fool |
| 01-Mar-13 05:02PM | 3 Humongous Health-Care Stocks This Week at Motley Fool |
| 11:15AM | Which of These 4 White Hot Drug Stocks Have the Strongest Earnings Trends? at Wall St. Cheat Sheet |
| 07:32AM | 4 Stocks Under $10 Moving Higher at TheStreet |
| 28-Feb-13 10:48AM | It's Now Time For Vivus Investors To Watch Arena Numbers at Seeking Alpha +9.78% |
| 09:48AM | A Drug That's Ready to Lose at Motley Fool |
| 08:30AM | Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference PR Newswire |
| 26-Feb-13 01:23PM | Vivus Reports Wider Loss Zacks |
| 25-Feb-13 06:57PM | Just 12,500% More Growth for an Obesity Blockbuster at Motley Fool |
| 02:39PM | Qysmia, the Hurdles, and Your Appetite for Risk at Motley Fool |
| 22-Feb-13 03:43PM | CHMP Still Negative on Vivus' Qsiva Zacks |
|
|
| Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Booth Mark D | Chief Commercial Officer | Mar 11 | Option Exercise | 1.66 | 27,685 | 45,957 | 27,685 | Mar 12 08:26 PM | | Booth Mark D | Chief Commercial Officer | Mar 11 | Sale | 6.67 | 27,685 | 184,659 | 0 | Mar 12 08:26 PM | | Booth Mark D | Chief Commercial Officer | Jan 15 | Option Exercise | 1.66 | 22,315 | 37,043 | 22,315 | Jan 18 06:02 AM | | Booth Mark D | Chief Commercial Officer | Jan 15 | Sale | 6.67 | 22,315 | 148,842 | 0 | Jan 18 06:02 AM | | Turner Heather D | SVP, Gen. Counsel & Secretary | Jul 17 | Option Exercise | 1.66 | 82,433 | 136,839 | 82,433 | Jul 19 07:59 PM | | NARACHI MICHAEL | President and CEO | Jul 17 | Option Exercise | 1.67 | 150,000 | 250,030 | 124,238 | Jul 19 08:07 PM | | NARACHI MICHAEL | President and CEO | Jul 17 | Sale | 7.66 | 150,000 | 1,149,000 | 0 | Jul 19 08:07 PM | | Turner Heather D | SVP, Gen. Counsel & Secretary | Jul 17 | Sale | 7.68 | 82,433 | 633,448 | 0 | Jul 19 07:59 PM | | NARACHI MICHAEL | President and CEO | Jul 13 | Option Exercise | 1.66 | 147,100 | 244,186 | 147,100 | Jul 13 08:13 PM | | Hagan Joseph P | Chief Business Officer | Jul 13 | Option Exercise | 1.66 | 30,000 | 49,800 | 30,000 | Jul 13 08:13 PM | | Hagan Joseph P | Chief Business Officer | Jul 13 | Sale | 6.77 | 30,000 | 203,000 | 0 | Jul 13 08:13 PM | | NARACHI MICHAEL | President and CEO | Jul 13 | Sale | 6.70 | 147,100 | 985,570 | 0 | Jul 13 08:13 PM | | NARACHI MICHAEL | President and CEO | Jul 12 | Option Exercise | 1.66 | 2,900 | 4,814 | 2,900 | Jul 13 08:13 PM | | NARACHI MICHAEL | President and CEO | Jul 12 | Sale | 6.66 | 2,900 | 19,314 | 0 | Jul 13 08:13 PM | | NARACHI MICHAEL | President and CEO | Jun 29 | Option Exercise | 1.66 | 125,000 | 207,500 | 125,000 | Jun 29 06:58 PM | | Hagan Joseph P | Chief Business Officer | Jun 29 | Option Exercise | 1.66 | 12,000 | 19,920 | 12,000 | Jun 29 06:58 PM | | Hagan Joseph P | Chief Business Officer | Jun 29 | Sale | 6.30 | 12,000 | 75,600 | 0 | Jun 29 06:58 PM | | NARACHI MICHAEL | President and CEO | Jun 29 | Sale | 6.08 | 125,000 | 760,000 | 0 | Jun 29 06:58 PM | | Booth Mark D | Chief Commercial Officer | Jun 28 | Option Exercise | 1.66 | 103,309 | 171,493 | 103,309 | Jun 29 06:58 PM | | NARACHI MICHAEL | President and CEO | Jun 28 | Option Exercise | 1.66 | 100,000 | 166,000 | 100,000 | Jun 29 06:58 PM | | Hagan Joseph P | Chief Business Officer | Jun 28 | Option Exercise | 1.66 | 26,000 | 43,160 | 26,000 | Jun 29 06:58 PM | | Hagan Joseph P | Chief Business Officer | Jun 28 | Sale | 5.90 | 26,000 | 153,400 | 0 | Jun 29 06:58 PM | | NARACHI MICHAEL | President and CEO | Jun 28 | Sale | 5.66 | 100,000 | 566,000 | 0 | Jun 29 06:58 PM | | Booth Mark D | Chief Commercial Officer | Jun 28 | Sale | 5.66 | 103,309 | 584,729 | 0 | Jun 29 06:58 PM | | Hagan Joseph P | Chief Business Officer | Jun 27 | Option Exercise | 1.66 | 70,000 | 116,200 | 70,000 | Jun 29 06:58 PM | | Hagan Joseph P | Chief Business Officer | Jun 27 | Sale | 5.26 | 70,000 | 368,000 | 0 | Jun 29 06:58 PM |
|
|
|
|
|
|
